Drug reference

latanoprostene bunod

Prostaglandin analogue; Nitric oxide donor · Antiglaucoma agent

Prostaglandin analogue; Nitric oxide donorAntiglaucoma agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

A newer PG analogue with a nitric oxide donating moiety that enhances traditional outflow through the trabecular meshwork by inducing relaxation of cytoskeleton, in addition to the effect of the latanoprost backbone on the uveoscleral pathway.

Indications

glaucomaocular hypertension

Side effects

Common

lash growthallergic conjunctival hyperemiapermanent increase in iris pigmentationorbital fat atrophy

Related guidelines

Beta-blockers in hypertension

MOHFW · Cardiology · 2024

Hypertension in diabetes

MOHFW · Endocrinology · 2024

Hypertension in adults

OTHER · Cardiology · 2022

Hypertension in diabetes

RSSDI · Endocrinology · 2022

Glaucoma

AIOS · Ophthalmology · 2022

Ask House about latanoprostene bunod

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team